Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 21;25(1):1196.
doi: 10.1186/s12885-025-14589-9.

Assessing factors influencing participation in LDCT lung cancer screening among high-risk urban populations in Nanjing, China

Meijing Liu #  1 , Suqin Huang #  2 , Ziru Yu  1 , Liling Dai  1 , Jin Xiang  1 , Yuan Qu  1 , Xiuming Zhang  1 , Wei Qiao  1 , Yan Chen  1 , Hairong Zhou  3 , Longbiao Zhu  4 , Chao Qin  5 , Jing Han  6
Affiliations

Assessing factors influencing participation in LDCT lung cancer screening among high-risk urban populations in Nanjing, China

Meijing Liu et al. BMC Cancer. .

Abstract

Background: Lung cancer remains a leading cause of cancer-related mortality in urban China, underscoring the urgency of effective screening programs. Despite the proven efficacy of low-dose computed tomography (LDCT) in reducing lung cancer mortality, participation rates among high-risk populations remain suboptimal. This study aspired to determine factors influencing LDCT screening adherence among high-risk individuals in Nanjing, China, as part of the China Urban Cancer Screening Project (CanSPUC).

Methods: A cross-sectional study was conducted from 2019 to 2023, involving 52,910 participants aged 45-74 years. High-risk individuals were identified using a modified Harvard Risk Index adjusted for Chinese demographics. Socio-demographic and clinical data were collected via questionnaires and LDCT reports, with missing values imputed via random forest models. Logistic regression was used to determine the factors associated with LDCT screening adherence.

Results: Among 16,020 high-risk participants, only 45.4% (7,280/16,020) underwent LDCT. Key factors influencing participation included gender (OR = 1.36, 95% CI:1.24-1.49, p < 0.001), education level (OR = 1.18, 95%CI:1.10-1.26, p < 0.001), occupational exposure (OR = 1.20, 95%CI: 1.11-1.29, p < 0.001), current smoking (OR = 1.26, 95%CI:1.13-1.40, p < 0.001), family cancer history (OR = 1.37, 95%CI:1.28-1.46, p < 0.001), and tuberculosis history (OR = 0.84, 95%CI:0.72-0.97, p = 0.022). LDCT detected lung cancer in 0.47% (34/7,280), with semi-positive nodules observed in 43.16% (3,142/7,280) of screened individuals.

Conclusions: Despite effective risk stratification, participation in LDCT screening remains low in urban China. Targeted interventions to solve gender disparities, health literacy gaps, and risk communication may be very important to improve the intake rate. Perhaps future efforts should give priority to community-based education, enhanced accessibility, and tailored protocols to reduce lung cancer mortality in high-risk populations.

Keywords: Adherence; Early detection; High-risk population screening; LDCT; Lung cancer.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Committee of Jiangsu cancer Hospital (Approval No.KY-2024-030). All procedures were performed in accordance with the ethical standards of the institutional and national research committees and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All patients signed informed consent prior to participant. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of participant recruitment in CanSPUC, 2019–2023
Fig. 2
Fig. 2
Detection rates of lung cancer and pulmonary nodules stratified by age and gender
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624–39. - PubMed
    1. Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 2024;93: 102693. - PubMed
    1. Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47–53. - PMC - PubMed
    1. Global cancer burden. growing, amidst mounting need for services. Saudi Med J. 2024;45(3):326–7. - PMC - PubMed
    1. Cancer - Screening. and early detection https://www.who.int/europe/news-room/fact-sheets/item/cancer-screening-a...